--- title: "Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared \"aspirational.\"" description: "Hims & Hers stock plummeted 27% after announcing it will cease selling compounded semaglutide, following the FDA's removal of the drug from its shortage list. This decision threatens the company's gro" type: "news" locale: "en" url: "https://longbridge.com/en/news/229659777.md" published_at: "2025-02-26T00:38:51.000Z" --- # Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational." > Hims & Hers stock plummeted 27% after announcing it will cease selling compounded semaglutide, following the FDA's removal of the drug from its shortage list. This decision threatens the company's growth, as GLP-1 drugs contributed 15% to its 2024 revenue of $1.48 billion, which grew by 69%. Analysts at Citi expressed skepticism about the company's future revenue guidance, deeming it "aspirational" given the loss of a key growth driver. The stock has fallen 49% from its recent peak, reflecting concerns over its valuation and competition in the obesity drug market. Courtesy of Hims & Hers - Hims & Hers stock fell by 27% as it announced plans to stop selling commercially available compounded semaglutide. - The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales strategy. - Hims & Hers' revenue grew by 69% in 2024, with GLP-1 drugs representing about 15% of sales. **The move:** Hims & Hers stock plunged by as much as 27% on Tuesday, hitting an intraday low of $37.29. The stock is down by 49% from its peak of $72.98 last week. **The chart:** **Why:** Hims & Hers said it would soon stop selling commercially available compounded versions of popular GLP-1 drugs. "We will remove all commercially available doses" of semaglutide, the company's chief financial officer, Yemi Okupe, said after the company released its fourth-quarter earnings on Monday. Last week, the Food and Drug Administration removed semaglutide, the active ingredient in Ozempic, from its shortage list. The FDA allows for the sale of compounded versions of drugs on its shortage list to limit patient supply issues. In 2022, the FDA placed semaglutide on the shortage list, opening the door for Hims & Hers to sell copycat versions of the drug. While it is phasing out commercially available doses of its weight-loss drug, the company said it would still offer "personalized doses of semaglutide as clinically necessary." **What it means:** Hims & Hers' business boomed over the past year thanks to sales of its compounded GLP-1 drugs. Revenue surged by 69%, to $1.48 billion, in 2024, with the drugs making up about 15% of those sales. That boom in business translated into a booming stock price: Its shares have more than tripled since November. But with the company's main source of growth set to be extinguished, its unclear how it can sustain its lofty valuation, with the stock trading at a price-to-earnings ratio of about 87x. Emphasizing the stiff competition in the market for obesity drugs, Eli Lilly, which sells its own GLP-1 drugs, announced on Tuesday that it would lower the price of its drugs in vial form for people paying out of pocket rather than using insurance. **What the pros are saying:** Citi estimated that GLP-1 drugs accounted for over $130 million of Hims & Hers' revenue in the fourth quarter, with very little growth for the company outside the drugs. "Now that semaglutide is off shortage, we think revenue guidance (56-63% y/y growth) is aspirational as it assumes $725M of revenue from weight loss products," analysts at Citi said. Read the original article on Business Insider ### Related Stocks - [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md) - [C.US - Citigroup](https://longbridge.com/en/quote/C.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 早盘趋势｜Hims & Hers Health 连续回踩，短线资金要抢反弹了吗？ | Hims & Hers Health（HIMS.US）昨夜承压继续下探，数字健康板块本周明显资金流出，但已经靠近关键技术支撑位，场内短线交易员们悄悄互问 “反弹资金是不是要来了？” 近期公司无重大战略消息，无新融资、并购、合作亮点，行业关注 | [Link](https://longbridge.com/en/news/272316089.md) | | 期权热点｜周二 HIMS 大跌 10%，部分看跌期权飙升 154% | 美东时间 02 月 10 日，HIMS 期权总成交 200580 张，看涨期权占比 60%，看跌期权占比 39%。 | [Link](https://longbridge.com/en/news/275549522.md) | | 高院否决，特朗普将被迫退税！华尔街 “早就下注”，商务部长儿子甚至一度参与 | 去年 10 月投资机构以每美元 20-40 美分的折扣价从进口商手中购入关税退款索赔权，单笔交易规模多在 200 万至 2000 万美元。投资者有望获得超 8 倍回报。但退款前景仍存不确定性，涉及金额达数十亿美元，各方仍在观望。 | [Link](https://longbridge.com/en/news/276502404.md) | | 传言成真？英伟达对 OpenAI 的 “1000 亿美元投资” 最终 “打了三折” | 据报道，英伟达正接近敲定对 OpenAI 最高 300 亿美元的股权投资，取代此前官宣的 1000 亿美元合作框架。原有协议因条款分歧与内部疑虑未能落地，黄仁勋亦曾强调其不具约束力。此次新融资轮规模或超 1000 亿美元，OpenAI 估值 | [Link](https://longbridge.com/en/news/276507066.md) | | 都想学英伟达 “芯片换融资”，谷歌和 AMD 都要扶持 “AI 云” | 谷歌正试图复制英伟达的成功路径，利用金融实力构建芯片生态系统。公司正洽谈向 “新型云” 公司 Fluidstack 注资约 1 亿美元，并为 Hut 8 等转型矿企提供项目融资支持，以换取 TPU 芯片的采用。AMD 则更为激进，为初创公司 | [Link](https://longbridge.com/en/news/276502552.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.